-
The S.A.F.E. Study is an abbreviation for: S.F.T. Alternative for Enoxaparin.
- The S.A.F.E. Study is the first (and only known study to MCS), which compares a device, head to head with enoxaparin, for the full recommended prophylaxis period.
- The S.A.F.E. Study endpoints were defined as VTE and bleeding complications.
- The S.A.F.E. Study was conducted on more than 400 patients who underwent THA surgery and who completed full recommended ten-day prophylaxis treatment both in-hospital and post discharge.
- Based upon these outstanding study results, it is clear that with the use of a light, portable, and easy-to-use device that generates a unique hemodynamic profile, such as the ActiveCare+S.F.T., THA patients can be mobilized rapidly with similar protection against thromboembolism as with the use of enoxaparin and with a lower incidence in major bleeding.
- The S.A.F.E. Study is published in: JBJS, March 2010; 92 (3): 527-535.
To view the complete study
,
refer to the S.A.F.E. Study
